Ann: OSX Successfully transitions to EU Medical Device Regulation, page-3

....and may the growing revenues resume again.

Typical Aussie bio-tech. Great products, very questionable management. Ran the well dry for no apparent reason whilst interest rates went up and liquidity went down. Understand long term holders being peed off, but frankly selling under the raise price a bit silly. Have happily bought down here. The balance sheet is going to be skinny for a while, but if they resume recent revenue growth, they will not need to dip in the markets for cash in a couple of years.

Whilst actual sales are still far too low, its got a big geographical footprint and we all know the, at least touted, superiority of its products to existing products in the market.